Cost-effectiveness analysis of tarlatamab as second-line therapy for small-cell lung cancer after platinum-based chemotherapy

Zhengxiong Li, Jiaming Zhu, Kai Ma

DOI: 10.6084/m9.figshare.34954076.v1
Published: 2026
Container: Not recorded
Publisher: Taylor & Francis
Open access: yes

Credibility signals

limited evidence Score 47/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingPublication license: A publication license was supplied: https://creativecommons.org/licenses/by/4.0/legalcode. Presence improves reuse transparency, not research validity. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.6084/m9.figshare.34954076.v1,
  title = {Cost-effectiveness analysis of tarlatamab as second-line therapy for small-cell lung cancer after platinum-based chemotherapy},
  author = {Zhengxiong Li and Jiaming Zhu and Kai Ma},
  year = {2026},
  doi = {10.6084/m9.figshare.34954076.v1},
  url = {https://doi.org/10.6084/m9.figshare.34954076.v1}
}

RIS

TY  - JOUR
TI  - Cost-effectiveness analysis of tarlatamab as second-line therapy for small-cell lung cancer after platinum-based chemotherapy
AU  - Zhengxiong Li
AU  - Jiaming Zhu
AU  - Kai Ma
PY  - 2026
DO  - 10.6084/m9.figshare.34954076.v1
UR  - https://doi.org/10.6084/m9.figshare.34954076.v1
ER  -

APA

Li, Z., Zhu, J., & Ma, K. (2026). Cost-effectiveness analysis of tarlatamab as second-line therapy for small-cell lung cancer after platinum-based chemotherapy. https://doi.org/10.6084/m9.figshare.34954076.v1

Source records

datacite · retrieved 2026-11-10T10:37:42.217Z